Emerging topical drugs for the treatment of rosacea

References

• Schaller M, Almeida LMC, Bewley A, et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel. Br J Dermatol. 2020;182:1269–1276.
   PubMed Web of Science ®Google Scholar
• Gether L, Overgaard LK, Egeberg A, et al. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol. 2018;179:282–289.
   PubMed Web of Science ®Google Scholar
• Woo YR, Lim JH, Cho DH, et al. Rosacea: molecular mechanisms and management of a chronic cutaneous inflammatory condition. Int J Mol Sci. 2016 15;17(9):E1562.
   PubMed Web of Science ®Google Scholar
• Alexis AF, Callender VD, Baldwin HE, et al. Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: review and clinical practice experience. J Am Acad Dermatol. 2019;80:1722–1729. e7 .
   PubMed Web of Science ®Google Scholar
• Rainer BM, Kang S, Chien AL. Rosacea: epidemiology, pathogenesis, and treatment. Dermatoendocrinol. 2018;4:9:e1361574.
   Google Scholar
• Picardo M, Eichenfield LF, Tan J. Acne and rosacea. Dermatol Ther (Heidelb). 2017;7:43–52.
   PubMed Web of Science ®Google Scholar
• Del Rosso JQ, Tanghetti E, Webster G, et al. Update on the management of rosacea from the American Acne & Rosacea Society (AARS). J Clin Aesthet Dermatol. 2019;12:17–24.
   PubMedGoogle Scholar
• Wang YA, James WD. Update on rosacea classification and its controversies. Cutis. 2019;104:70–73.
   PubMed Web of Science ®Google Scholar
• Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: the 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018;78:148–155.
   PubMed Web of Science ®Google Scholar
• Buddenkotte J, Steinhoff M. Recent advances in understanding and managing rosacea. F1000Res. 2018;7:F1000.
   PubMedGoogle Scholar
• Ahn CS, Huang WW. Rosacea pathogenesis. Dermatol Clin. 2018;36:81–86.
   PubMed Web of Science ®Google Scholar
• Holmes AD, Steinhoff M. Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics. Exp Dermatol. 2017;26:659–667.
   PubMed Web of Science ®Google Scholar
• Awosika O, Oussedik E. Genetic predisposition to rosacea. Dermatol Clin. 2018;36:87–92.
   PubMed Web of Science ®Google Scholar
• Aldrich N, Gerstenblith M, Fu P, et al. Genetic vs environmental factors that correlate with rosacea: a cohort-based survey of twins. JAMA Dermatol. 2015;151:1213–1219.
   PubMed Web of Science ®Google Scholar
• Chang ALS, Raber I, Xu J, et al. Assessment of the genetic basis of rosacea by genome-wide association study. J Invest Dermatol. 2015;135:1548–1555.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang YJ, Hao D, et al. The theranostics role of mast cells in the pathophysiology of rosacea. Front Med (Lausanne). 2020. DOI:10.3389/fmed.2019.00324.
   Google Scholar
• Li T, Zeng Q, Chen X, et al. The therapeutic effect of artesunate on rosacea through the inhibition of the JAK/STAT signaling pathway. Mol Med Rep. 2018;17:8385–8390.
   PubMed Web of Science ®Google Scholar
• Two AM, Wu W, Gallo RL, et al. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors. J Am Acad Dermatol. 2015;72:749–758.
   PubMed Web of Science ®Google Scholar
• Aubdool AA, Brain SD. Neurovascular aspects of skin neurogenic inflammation. J Investig Dermatol Symp Proc. 2011;15:33–39.
   PubMed Web of Science ®Google Scholar
• Jones DA. Rosacea, reactive oxygen species, and azelaic acid. J Clin Aesthet Dermatol. 2009;2:26–30.
   PubMedGoogle Scholar
• Marson JW, Baldwin HE. Rosacea: a wholistic review and update from pathogenesis to diagnosis and therapy. Int J Dermatol. 2020;59:e175–e182.
   PubMed Web of Science ®Google Scholar
• Forton FM. Papulopustular rosacea, skin immunity and Demodex: pityriasis folliculorum as a missing link. J Eur Acad Dermatol Venereol. 2012;26:19–28.
   PubMed Web of Science ®Google Scholar
• Tan J, Steinhoff M, Bewley A, et al. Characterizing high-burden rosacea subjects: a multivariate risk factor analysis from a global survey. J Dermatolog Treat. 2020;31:168–174.
   PubMed Web of Science ®Google Scholar
• Harper J, Del Rosso JQ, Ferrusi IL. Cross-Sectional survey of the burden of illness of rosacea by erythema severity. J Drugs Dermatol. 2018;17:150–158.
   PubMed Web of Science ®Google Scholar
• Tan J, Almeida LM, Bewley A, et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176:431–438.
   PubMed Web of Science ®Google Scholar
• Dirschka T, Micali G, Papadopoulos L, et al. Perceptions on the psychological impact of facial erythema associated with rosacea: results of international survey. Dermatol Ther (Heidelb). 2015;5:117–127.
   PubMed Web of Science ®Google Scholar
• Culp B, Scheinfeld N. Rosacea: a review. PT. 2009;34:38–45.
   PubMedGoogle Scholar
• Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents. Cutis. 2013;92:277–284.
   PubMed Web of Science ®Google Scholar
• Thiboutot DM, Fleischer AB Jr, Del Rosso JQ, et al. Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol. 2008;7:541–546.
   PubMed Web of Science ®Google Scholar
• Coda AB, Hata T, Miller J, et al. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol. 2013;69:570–577.
   PubMed Web of Science ®Google Scholar
• Del Rosso JQ, Bhatia N. Azelaic acid gel 15% in the management of papulopustular rosacea: a status report on available efficacy data and clinical application. Cutis. 2011;88:67–72.
   PubMed Web of Science ®Google Scholar
• van Zuuren EJ, Fedorowicz Z, Carter B, et al. Interventions for rosacea. Cochrane Database Syst Rev. 2015;2015(4):CD003262.
   PubMedGoogle Scholar
• Del Rosso JQ. Azelaic acid topical formulations: differentiation of 15% gel and 15% foam. J Clin Aesthet Dermatol. 2017;10:37–40.
   PubMedGoogle Scholar
• McClellan KJ, Noble S. Topical metronidazole. A review of its use in rosacea. Am J Clin Dermatol. 2000;1:191–199. .
   PubMedGoogle Scholar
• McGregor SP, Alinia H, Snyder A, et al. A review of the current modalities for the treatment of papulopustular rosacea. Dermatol Clin. 2018;36:135–150.
   PubMed Web of Science ®Google Scholar
• Del Rosso JQ. A status report on the medical management of rosacea: focus on topical therapies. Cutis. 2002;70:271–275.
   PubMed Web of Science ®Google Scholar
• Trumbore MW, Goldstein JA, Gurge RM. Treatment of papulopustular rosacea with sodium sulfacetamide 10%/sulfur 5% emollient foam. J Drugs Dermatol. 2009;8:299–304.
   PubMedGoogle Scholar
• Torok HM, Webster G, Dunlap FE, et al. Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. Cutis. 2005;75:357–363.
   PubMed Web of Science ®Google Scholar
• Abokwidir M, Feldman SR. Rosacea management. Skin Appendage Disord. 2016;2:26–34.
   PubMed Web of Science ®Google Scholar
• Anderson MS, Nadkarni A, Cardwell LA, et al. Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability. Patient Prefer Adherence. 2017;11:1143–1150.
   PubMed Web of Science ®Google Scholar
• Jackson JM, Knuckles M, Minni JP, et al. The role of brimonidine tartrate gel in the treatment of rosacea. Clin Cosmet Investig Dermatol. 2015;8:529–538.
   PubMed Web of Science ®Google Scholar
• Kim M, Kim J, Jeong SW, et al. Inhibition of mast cell infiltration in an LL-37-induced rosacea mouse model using topical brimonidine tartrate 0.33% gel. Exp Dermatol. 2017;26:1143–1145.
   PubMed Web of Science ®Google Scholar
• Piwnica D, Rosignoli C, de Ménonville ST, et al. Vasoconstriction and anti-inflammatory properties of the selective α-adrenergic receptor agonist brimonidine. J Dermatol Sci. 2014;75:49–54.
   PubMed Web of Science ®Google Scholar
• Bertino B, Blanchet-Réthoré S, Thibaut de Ménonville S, et al. Brimonidine displays anti-inflammatory properties in the skin through the modulation of the vascular barrier function. Exp Dermatol. 2018;27:1378–1387.
   PubMed Web of Science ®Google Scholar
• Fowler J, Jarratt M, Moore A, et al. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle controlled studies. Br J Dermatol. 2012;166:633–641.
   PubMed Web of Science ®Google Scholar
• Fowler JJ, Jackson M, Moore A, et al. Efficacy and safety of once daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol. 2013;12:650–656.
   PubMed Web of Science ®Google Scholar
• Jackson JM, Fowler J, Moore A, et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. J Drugs Dermatol. 2014;13:699–704.
   PubMed Web of Science ®Google Scholar
• Layton AM, Schaller M, Homey B, et al. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle controlled study. J Eur Acad Dermatol Venereol. 2015;29:2405–2410.
   PubMed Web of Science ®Google Scholar
• Moore A, Kempers S, Murakawa G, et al. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol. 2014;13:56–61.
   PubMed Web of Science ®Google Scholar
• Gold LS, Papp K, Lynde C, et al. Treatment of rosacea with concomitant use of topical ivermectin 1% cream and brimonidine 0.33% gel: a randomized, vehicle-controlled study. J Drugs Dermatol. 2017;16:909–916.
   PubMed Web of Science ®Google Scholar
• Tong LX, Moore AY. Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea. Expert Rev Clin Pharmacol. 2014;7:567–577.
   PubMed Web of Science ®Google Scholar
• Micali G, Gerber PA, Lacarrubba F, et al. Improving treatment of erythematotelangiectatic rosacea with laser and/or topical therapy through enhanced discrimination of its clinical features. J Clin Aesthet Dermatol. 2016;9:30–39.
   PubMedGoogle Scholar
• Micali G, Dall’Oglio F, Verzì AE, et al. Treatment of erythemato-telangiectatic rosacea with brimonidine alone or combined with vascular laser based on preliminary instrumental evaluation of the vascular component. Lasers Med Sci. 2018;33:1397–1400.
   PubMed Web of Science ®Google Scholar
• Dall’Oglio F, Verzi AE, Lacarrubba F, et al. Inter-observer evaluation of erythema-directed photography for the assessment of erythema and telangiectasias in rosacea. Skin Res Technol. 2020 Nov 3. DOI:10.1111/srt.12979.
   PubMed Web of Science ®Google Scholar
• Cline A, McGregor SP, Feldman SR. Medical management of facial redness in rosacea. Dermatol Clin. 2018;36:151–159.
   PubMed Web of Science ®Google Scholar
• Lowe E, Lim S. Paradoxical erythema reaction of long-term topical brimonidine gel for the treatment of facial erythema of rosacea. J Drugs Dermatol. 2016;15:763–765.
   PubMed Web of Science ®Google Scholar
• Tanghetti EA, Jackson JM, Belasco KT, et al. Optimizing the use of topical brimonidine in rosacea management: panel recommendations. J Drugs Dermatol. 2015;14:33–40.
   PubMed Web of Science ®Google Scholar
• Okwundu N, Cline A, Feldman SR. Difference in vasoconstrictors: oxymetazoline vs. brimonidine. J Dermatolog Treat. 2019;1–7. DOI:10.1080/09546634.2019.1639606
   Web of Science ®Google Scholar
• Feaster B, Cline A, Feldman SR, et al. Clinical effectiveness of novel rosacea therapies. Curr Opin Pharmacol. 2019;46:14–18.
   PubMed Web of Science ®Google Scholar
• Tanghetti EA, Dover JS, Goldberg DJ, et al. Clinically relevant reduction in persistent facial erythema of rosacea on the first day of treatment with oxymetazoline cream 1. J Drugs Dermatol. 2018;17:621–626.
   PubMed Web of Science ®Google Scholar
• Kuang AW, DuBois J, Attar M, et al. Clinical pharmacokinetics of oxymetazoline cream following topical facial administration for the treatment of erythema associated with rosacea. J Drugs Dermatol. 2018;17:213–220.
   PubMed Web of Science ®Google Scholar
• DuBois J, Dover JS, Jones TM, et al. Phase 2 randomized, dose-ranging study of oxymetazoline cream for treatment of persistent facial erythema associated with rosacea. J Drugs Dermatol. 2018;17:308–316.
   PubMed Web of Science ®Google Scholar
• Kircik LH, DuBois J, Draelos ZD, et al. Pivotal trial of the efficacy and safety of oxymetazoline cream 1.0% for the treatment of persistent facial erythema associated with rosacea: findings from the first REVEAL trial. J Drugs Dermatol. 2018;17:97–105.
   PubMed Web of Science ®Google Scholar
• Baumann L, Goldberg DJ, Stein Gold L, et al. Pivotal trial of the efficacy and safety of oxymetazoline cream 1.0% for the treatment of persistent facial erythema associated with rosacea: findings from the second REVEAL trial. J Drugs Dermatol. 2018;17:290–298.
   PubMed Web of Science ®Google Scholar
• Draelos ZD, Gold MH, Weiss RA, et al. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 52-week open label REVEAL trial. J Am Acad Dermatol. 2018;78:1156–1163.
   PubMed Web of Science ®Google Scholar
• Tanghetti EA, Goldberg DJ, Dover JS, et al. Oxymetazoline and energy-based therapy in patients with rosacea: evaluation of the safety and tolerability in an open-label, interventional study. Lasers Surg Med. 2020. DOI:10.1002/lsm.23253.
   Web of Science ®Google Scholar
• Schaller M, Gonser L, Belge K, et al. Dual anti-inflammatory and anti-parasitic action of topical ivermectin 1% in papulopustular rosacea. J Eur Acad Dermatol Venereol. 2017;31:1907–1911.
   PubMed Web of Science ®Google Scholar
• Siddiqui K, Stein Gold L, Gill J. The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta-analysis. Springerplus. 2016;5:1151.
   PubMedGoogle Scholar
• Husein-El Ahmed H, Steinhoff M. Efficacy of topical ivermectin and impact on quality of life in patients with papulopustular rosacea: a systematic review and meta-analysis. Dermatol Ther. 2020;33:e13203.
   PubMed Web of Science ®Google Scholar
• Ebbelaar CCF, Venema AW, Van Dijk MR. Topical ivermectin in the treatment of papulopustular rosacea: a systematic review of evidence and clinical guideline recommendations. Dermatol Ther (Heidelb). 2018;8:379–387.
   PubMed Web of Science ®Google Scholar
• Dall’Oglio F, Lacarrubba F, Luca M, et al. Clinical and erythema-directed imaging evaluation of papulo-pustular rosacea with topical ivermectin: a 32 weeks duration study. J Dermatolog Treat. 2019;30:703–707.
   PubMed Web of Science ®Google Scholar
• Garrido-Mesa N, Zarzuelo A, Gálvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013;169:337–352.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Kedem TH, Keynan R, et al. A Phase II, randomized, double-blind clinical study evaluating the safety, tolerability, and efficacy of a topical minocycline foam, FMX103, for the Treatment of facial papulopustular rosacea. Am J Clin Dermatol. 2018;19:427–436.
   PubMed Web of Science ®Google Scholar
• Gold LS, Del Rosso JQ, Kircik L, et al. Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: results of 2 Phase 3, randomized, clinical trials. J Am Acad Dermatol. 2020;82:1166–1173.
   PubMed Web of Science ®Google Scholar
• Webster G, Draelos ZD, Graber E, et al. A multicentre, randomized, double-masked, parallel group, vehicle-controlled Phase IIb study to evaluate the safety and efficacy of 1% and 3% topical minocycline gel in patients with papulopustular rosacea. Br J Dermatol. 2020;183:471–479.
   PubMed Web of Science ®Google Scholar
• Schaller M, Schöfer H, Homey B, et al. Rosacea management: update on general measures and topical treatment options. J Dtsch Dermatol Ges. 2016;14:17–27.
   Web of Science ®Google Scholar
• Lee DH, Li K, Suh DH. Pimecrolimus 1% cream for the treatment of steroid-induced rosacea: an 8-week split-face clinical trial. Br J Dermatol. 2008;158:1069–1076.
   PubMed Web of Science ®Google Scholar
• Wollina U. Recent advances in the understanding and management of rosacea. F1000Prime Rep. 2014;6:50.
   PubMedGoogle Scholar
• Wozniacka A, Wieczorkowska M, Gebicki J, et al. Topical application of 1-methylnicotinamide in the treatment of rosacea: a pilot study. Clin Exp Dermatol. 2005;30:632–665.
   PubMed Web of Science ®Google Scholar
• Forton FMN, De Maertelaer V. Treatment of rosacea and demodicosis with benzyl benzoate: effects of different doses on Demodex density and clinical symptoms. J Eur Acad Dermatol Venereol. 2020;34:365–369.
   PubMed Web of Science ®Google Scholar
• Ebneyamin E, Mansouri P, Rajabi M, et al. The efficacy and safety of permethrin 2.5% with tea tree oil gel on rosacea treatment: a double-blind, controlled clinical trial. J Cosmet Dermatol. 2020;19:1426–1431.
   PubMed Web of Science ®Google Scholar
• Jacob S, VanDaele MA, Brown JN. Treatment of Demodex-associated inflammatory skin conditions: a systematic review. Dermatol Ther. 2019;32:e13103.
   PubMed Web of Science ®Google Scholar
• Bribeche MR, Fedotov VP, Gladichev VV, et al. Clinical and experimental assessment of the effects of a new topical treatment with praziquantel in the management of rosacea. Int J Dermatol. 2015;54:481–487.
   PubMed Web of Science ®Google Scholar
• Bikowski JB, Del Rosso JQ. Demodex dermatitis: a retrospective analysis of clinical diagnosis and successful treatment with topical crotamiton. J Clin Aesthet Dermatol. 2009;2:20–25.
   PubMedGoogle Scholar
• Anzengruber F, Czernielewski J, Conrad C, et al. Swiss S1 guideline for the treatment of rosacea. J Eur Acad Dermatol Venereol. 2017;31:1775–1791.
   PubMed Web of Science ®Google Scholar
• Chang AL, Alora-Palli M, Lima XT, et al. A randomized, double-blind, placebo-controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeks. J Drugs Dermatol. 2012;11:333–339.
   PubMed Web of Science ®Google Scholar
• Merlo G, Cozzani E, Russo R, et al. Dapsone for unresponsive granulomatous rosacea. Am J Ther. 2020;27:e304–e306.
   PubMed Web of Science ®Google Scholar
• Faghihi G, Khosravani P, Nilforoushzadeh MA, et al. Dapsone gel in the treatment of papulopustular rosacea: a double-blind randomized clinical trial. J Drugs Dermatol. 2015;14:602–606.
   PubMed Web of Science ®Google Scholar
• Bageorgou F, Vasalou V, Tzanetakou V, et al. The new therapeutic choice of tranexamic acid solution in treatment of erythematotelangiectatic rosacea. J Cosmet Dermatol. 2019;18:563–567.
   PubMed Web of Science ®Google Scholar
• Fernández JR, Webb C, Rouzard K, et al. SIG1459: a novel phytyl-cysteine derived TLR2 modulator with in vitro and clinical anti-acne activity. Exp Dermatol. 2018;27:993–999.
   PubMed Web of Science ®Google Scholar
• Lee YW, Won CH, Jung K, et al. Efficacy and safety of PAC-14028 cream a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase IIb randomized trial. Br J Dermatol. 2019;180:1030–1038.
   PubMed Web of Science ®Google Scholar
• Li YF, Chen XY, Lei TC. Inhibitory effect of timolol on topical glucocorticoid-induced skin telangiectasia. Mol Med Rep. 2018;18:2823–2831.
   PubMed Web of Science ®Google Scholar
• Stover K, Fukuyama T, Young AT, et al. Topically applied manganese-porphyrins BMX-001 and BMX-010 display a significant anti-inflammatory response in a mouse model of allergic dermatitis. Arch Dermatol Res. 2016;308:711–721.
   PubMed Web of Science ®Google Scholar
• [cited 2020 Sep 3]. Available from: https://adisinsight.springer.com/drugs/800044204
   Google Scholar
• Korting HC, Schöllmann C. Current topical and systemic approaches to treatment of rosacea. J Eur Acad Dermatol Venereol. 2009;23:876–882.
   PubMed Web of Science ®Google Scholar
• Freeman SA, Moon SD, Spencer JM. Clindamycin phosphate 1.2% and tretinoin 0.025% gel for rosacea: summary of a placebo-controlled, double-blind trial. J Drugs Dermatol. 2012;11:1410–1414.
   PubMed Web of Science ®Google Scholar
• [cited 2021 Jan 7]. Available from:https://rosacea-support.org/accuitis-to-trial-acu-d1-for-rosacea.html
   Google Scholar
• Lanier RK, Cohen AE, Weinkle SH. Effects of a facial cream containing the minor alkaloid anatabine on improving the appearance of the skin in mild to moderate rosacea: an open-label case series study. Case Rep Dermatol. 2013;5:347–355.
   PubMedGoogle Scholar
• Two AM, Hata TR, Nakatsuji T, et al. Reduction in serine protease activity correlates with improved rosacea severity in a small, randomized pilot study of a topical serine protease inhibitor. J Invest Dermatol. 2014;134:1143–1145.
   PubMed Web of Science ®Google Scholar
• Thompson BJ, Furniss M, Zhao W, et al. An oral phosphodiesterase inhibitor (apremilast) for inflammatory rosacea in adults: a pilot study. JAMA Dermatol. 2014;150:1013–1014.
   PubMed Web of Science ®Google Scholar
• Muto Y, Wang Z, Vanderberghe M, et al. Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea. J Investig Dermatol. 2014;134:2728–2736.
   PubMed Web of Science ®Google Scholar
• Rubinchik E, Dugourd D, Algara T, et al. Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonization models. Int J Antimicrob Agents. 2009;34:457–461.
   PubMed Web of Science ®Google Scholar
• Romanowicz M, Stephenson JJ, Del Rosso JQ, et al. Healthcare utilization and costs of patients with rosacea in an insured population. J Drugs Dermatol. 2008;7:41–49.
   PubMed Web of Science ®Google Scholar